Synergistic Effect of G-Eye Balloon for Behind the Folds Visualization With CADe (Discovery System) on Adenoma Detection Rate. (DiscoveryIII)
Primary Purpose
Colorectal Polyp, Colonoscopy, Artificial Intelligence
Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
colonoscopy assisted by both balloon-Behind The Folds visualizing and Computer assisted detection (CADe)
Sponsored by
About this trial
This is an interventional diagnostic trial for Colorectal Polyp
Eligibility Criteria
Inclusion Criteria:
- Adult patients (>18 years)
- Referred and scheduled for diagnostic, screening (non-iFOBT based), or surveillance colonoscopy.
Exclusion Criteria:
- Inflammatory bowel disease (IBD)
- Known polyp or tumor upon referral
- Therapeutic procedure (e.g., endoscopic mucosal resection)
- Prior surgical resection of any portion of the colon
- American Society of Anesthesiologists score of ≥3
- Inadequately corrected anticoagulation disorder or anticoagulation medication use
- inability to provide informed consent.
Sites / Locations
- Radboud university medical center NijmegenRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
colonoscopy with a combined BFT and CADe assisted approach
Arm Description
This multicenter single-arm colonoscopy trial will compare colonoscopy assisted by both balloon-BFT visualizing and CADe to CADe-only assisted colonoscopy in diagnostic, screening (non-iFOBT based)), or surveillance colonoscopy. The latter group will be selected from the interventional arm from the Discovery II trial, using corresponding participating centers. All subjects in this trial will undergo the same treatment, i.e., combined balloon and CADe-assisted colonoscopy.
Outcomes
Primary Outcome Measures
Adenoma Detection Rate (ADR)
Calculated as the number of patients in whom at least one adenoma is detected during the colonoscopy procedure, divided by the total number of patients that underwent the colonoscopy procedure.
Secondary Outcome Measures
Advanced adenoma detection rate (AADR).
calculated as the number of patients in whom at least one advanced adenoma is detected during the colonoscopy procedure, divided by the total number of patients that underwent the colonoscopy procedure
Polyp Detection Rate
calculated as the number of patients in whom at least one polyp is detected during the colonoscopy procedure, divided by the total number of patients that underwent the colonoscopy procedure
Sessile detection Rate
calculated as the number of patients in whom at least one SSL is detected during the colonoscopy procedure, divided by the total number of patients that underwent the colonoscopy procedure
Indication specific ADR,
ADR specific for screening, diagnostic, or surveillance
Mean number of adenomas detected per patient
Mean number of adenomas detected per patient
Mean number of polyps detected per patient
Mean number of polyps detected per patient
Number of sessile serrated lesions
Number of sessile serrated lesions
Number of advanced adenomas (adenomas ≥ 10 mm and/or with a villous component and/or with HGD
Number of advanced adenomas (adenomas ≥ 10 mm and/or with a villous component and/or with HGD
Size of the lesion subdivided in categories 0-5 mm, 6-10 mm, 10-20 mm, >20 mm
Size of the lesion subdivided in categories 0-5 mm, 6-10 mm, 10-20 mm, >20 mm
Location of the lesion: cecum, ascending colon, transverse colon, descending colon, sigmoid, rectum;
Location of the lesion: cecum, ascending colon, transverse colon, descending colon, sigmoid, rectum;
Morphological characteristics of the lesion using the Paris classification (Ip, Is, IIa, IIb, IIc, III)
Morphological characteristics of the lesion using the Paris classification (Ip, Is, IIa, IIb, IIc, III)
Histopathological characteristics of the lesion according to the Vienna classification
Histopathological characteristics of the lesion according to the Vienna classification
ADR of the first 20% of patients that have undergone colonoscopy by each endoscopist will be compared with the final 20% of patients in each arm to identify any changes in ADR throughout the trial
ADR of the first 20% of patients that have undergone colonoscopy by each endoscopist will be compared with the final 20% of patients in each arm to identify any changes in ADR throughout the trial
Bowel cleansing
Using the Boston Bowel Prep Scale
Cecal intubation rate (CIR)
Cecal intubation rate (CIR)
Procedure times with both techniques (i.e., total procedure time, mean polypectomy time and withdrawal time)
Procedure times with both techniques (i.e., total procedure time, mean polypectomy time and withdrawal time)
Severe) adverse events (S)AEs up to 30 days post-procedure
SAEs will be subcategorized into colonoscopy related, cardiac (cardiac ischemia, heart failure, arrhythmia, other) pulmonary (exacerbation COPD, infectious, other), neurological (stroke, cerebrovascular accident, bleeding, other), and other (surgical interventions etc.)
Gloucester Comfort Scale score and analgesia use
Gloucester Comfort Scale score and analgesia use
Post-colonoscopy surveillance intervals when applying European and US surveillance guidelines
Post-colonoscopy surveillance intervals when applying European and US surveillance guidelines
Full Information
NCT ID
NCT05220345
First Posted
January 31, 2022
Last Updated
March 29, 2023
Sponsor
Radboud University Medical Center
Collaborators
PENTAX Europe GmbH
1. Study Identification
Unique Protocol Identification Number
NCT05220345
Brief Title
Synergistic Effect of G-Eye Balloon for Behind the Folds Visualization With CADe (Discovery System) on Adenoma Detection Rate.
Acronym
DiscoveryIII
Official Title
Synergistic Effect of G-Eye Balloon for Behind the Folds Visualization With Artificial Intelligence Assisted Polyp Detection (Discovery System) on Adenoma Detection Rate. 'Discovery III Study'
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 31, 2022 (Actual)
Primary Completion Date
September 30, 2023 (Anticipated)
Study Completion Date
October 30, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Radboud University Medical Center
Collaborators
PENTAX Europe GmbH
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Colonoscopy is the gold standard for colorectal screening. The diagnostic accuracy of colonoscopy highly depends on the quality of inspection of the colon during the procedure. To increase detection new polyp detection systems based on artificial intelligence (AI) have been developed. However, these systems still depend on the ability of the endoscopist to adequately visualize the complete colonic mucosa, especially to detect smaller and more subtle lesions, or lesions hidden behind folds in the colon. With this study we want to combine a device to flatten the folds in the colon combined with an artificial intelligence system to further improve the detection rate of lesions during colonoscopy.
Detailed Description
Rationale: Colonoscopy is the gold standard for CRC screening. The adenoma detection rate (ADR) is the most important quality parameter for colonoscopy, because of its inverse association with the risk of interval CRC. Yet, the adenoma miss rate (AMR) in conventional colonoscopy is reported in meta-analyses to vary between 22-26%. The diagnostic accuracy of colonoscopy highly depends on the quality of inspection of the colonic mucosa during the procedure. To increase the adenoma detection rate (ADR), new polyp/adenoma detection systems based on artificial intelligence (AI) have been developed, i.e., computer assisted detection (CADe). However, these systems still depend on the ability of the endoscopist to adequately visualize the complete colonic mucosa, especially to detect smaller and more subtle lesions. Therefore, we hypothesize that ADR can further be improved by combining a CADe system, the Discovery system, with a behind the fold (BTF) visualization technique, the G-Eye.
Study design: International multicenter prospective interventional cohort, compared with a cohort from the Discovery II study (NL73127.091.20, trial code NL9135). All subjects will be undergoing colonoscopy with a combined BFT and CADe assisted approach. Outcomes will be corrected for confounders using regression modeling.
Study population: 194 Adult patients (>18 years) from 3 hospitals, scheduled for diagnostic, screening (non-iFOBT based), or surveillance colonoscopy. Exclusion criteria: inflammatory bowel disease (IBD), known polyp or tumor upon referral, therapeutic procedure (e.g. endoscopic mucosal resection), prior surgical resection of any portion of the colon, American Society of Anesthesiologists score of ≥3, Inadequately corrected anticoagulation disorders or anticoagulation medication use, inability to provide informed consent.
Main study endpoints: The primary objective of the present study is to compare ADR between CADe assisted and a combined BTF/CADe assisted colonoscopy. Secondary objectives include advanced neoplasia rate (including advanced adenomas and/or CRC), polyp detection rate, size and histopathology, mean number of polyps per patient, procedure times, bowel cleaning levels, adverse events, inter-operator variability.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Eligible patients who are scheduled for surveillance colonoscopy will undergo one BFT and CADe assisted colonoscopy. There will be no burden for participants regarding the colonoscopy procedure. Colonoscopy is a commonly performed procedure, and the overall serious adverse event rate is low with an estimated risk 2.8 per 1000 colonoscopies. The risk of experiencing a (serious) adverse event with G-Eye and Discovery guided colonoscopy is believed to be equivalent to conventional colonoscopy. The benefit for patients is a higher likelihood of lesion detection during colonoscopy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Polyp, Colonoscopy, Artificial Intelligence, Adenoma
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
International multicenter prospective interventional cohort, compared with a cohort from the Discovery II study (NL73127.091.20, trial code NL9135).
Masking
None (Open Label)
Allocation
N/A
Enrollment
194 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
colonoscopy with a combined BFT and CADe assisted approach
Arm Type
Other
Arm Description
This multicenter single-arm colonoscopy trial will compare colonoscopy assisted by both balloon-BFT visualizing and CADe to CADe-only assisted colonoscopy in diagnostic, screening (non-iFOBT based)), or surveillance colonoscopy. The latter group will be selected from the interventional arm from the Discovery II trial, using corresponding participating centers. All subjects in this trial will undergo the same treatment, i.e., combined balloon and CADe-assisted colonoscopy.
Intervention Type
Device
Intervention Name(s)
colonoscopy assisted by both balloon-Behind The Folds visualizing and Computer assisted detection (CADe)
Intervention Description
All participants will be subjected to a colonoscopy procedure, assisted by both G-eye balloon and the Discovery CADe system. Standard of care regarding the colonoscopy procedure will be applied to all study subjects. Any lesions detected during the procedure will be removed directly
Primary Outcome Measure Information:
Title
Adenoma Detection Rate (ADR)
Description
Calculated as the number of patients in whom at least one adenoma is detected during the colonoscopy procedure, divided by the total number of patients that underwent the colonoscopy procedure.
Time Frame
30 days after procedure
Secondary Outcome Measure Information:
Title
Advanced adenoma detection rate (AADR).
Description
calculated as the number of patients in whom at least one advanced adenoma is detected during the colonoscopy procedure, divided by the total number of patients that underwent the colonoscopy procedure
Time Frame
30 days after procedure
Title
Polyp Detection Rate
Description
calculated as the number of patients in whom at least one polyp is detected during the colonoscopy procedure, divided by the total number of patients that underwent the colonoscopy procedure
Time Frame
30 days after procedure
Title
Sessile detection Rate
Description
calculated as the number of patients in whom at least one SSL is detected during the colonoscopy procedure, divided by the total number of patients that underwent the colonoscopy procedure
Time Frame
30 days after procedure
Title
Indication specific ADR,
Description
ADR specific for screening, diagnostic, or surveillance
Time Frame
30 days after procedure
Title
Mean number of adenomas detected per patient
Description
Mean number of adenomas detected per patient
Time Frame
30 days after procedure
Title
Mean number of polyps detected per patient
Description
Mean number of polyps detected per patient
Time Frame
30 days after procedure
Title
Number of sessile serrated lesions
Description
Number of sessile serrated lesions
Time Frame
30 days after procedure
Title
Number of advanced adenomas (adenomas ≥ 10 mm and/or with a villous component and/or with HGD
Description
Number of advanced adenomas (adenomas ≥ 10 mm and/or with a villous component and/or with HGD
Time Frame
30 days after procedure
Title
Size of the lesion subdivided in categories 0-5 mm, 6-10 mm, 10-20 mm, >20 mm
Description
Size of the lesion subdivided in categories 0-5 mm, 6-10 mm, 10-20 mm, >20 mm
Time Frame
During procedure
Title
Location of the lesion: cecum, ascending colon, transverse colon, descending colon, sigmoid, rectum;
Description
Location of the lesion: cecum, ascending colon, transverse colon, descending colon, sigmoid, rectum;
Time Frame
During procedure
Title
Morphological characteristics of the lesion using the Paris classification (Ip, Is, IIa, IIb, IIc, III)
Description
Morphological characteristics of the lesion using the Paris classification (Ip, Is, IIa, IIb, IIc, III)
Time Frame
During procedure
Title
Histopathological characteristics of the lesion according to the Vienna classification
Description
Histopathological characteristics of the lesion according to the Vienna classification
Time Frame
30 days after procedure
Title
ADR of the first 20% of patients that have undergone colonoscopy by each endoscopist will be compared with the final 20% of patients in each arm to identify any changes in ADR throughout the trial
Description
ADR of the first 20% of patients that have undergone colonoscopy by each endoscopist will be compared with the final 20% of patients in each arm to identify any changes in ADR throughout the trial
Time Frame
At end of study
Title
Bowel cleansing
Description
Using the Boston Bowel Prep Scale
Time Frame
During procedure
Title
Cecal intubation rate (CIR)
Description
Cecal intubation rate (CIR)
Time Frame
During procedure
Title
Procedure times with both techniques (i.e., total procedure time, mean polypectomy time and withdrawal time)
Description
Procedure times with both techniques (i.e., total procedure time, mean polypectomy time and withdrawal time)
Time Frame
During procedure
Title
Severe) adverse events (S)AEs up to 30 days post-procedure
Description
SAEs will be subcategorized into colonoscopy related, cardiac (cardiac ischemia, heart failure, arrhythmia, other) pulmonary (exacerbation COPD, infectious, other), neurological (stroke, cerebrovascular accident, bleeding, other), and other (surgical interventions etc.)
Time Frame
30 days after procedure
Title
Gloucester Comfort Scale score and analgesia use
Description
Gloucester Comfort Scale score and analgesia use
Time Frame
During procedure
Title
Post-colonoscopy surveillance intervals when applying European and US surveillance guidelines
Description
Post-colonoscopy surveillance intervals when applying European and US surveillance guidelines
Time Frame
30 days after procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Adult patients (>18 years)
Referred and scheduled for diagnostic, screening (non-iFOBT based), or surveillance colonoscopy.
Exclusion Criteria:
Inflammatory bowel disease (IBD)
Known polyp or tumor upon referral
Therapeutic procedure (e.g., endoscopic mucosal resection)
Prior surgical resection of any portion of the colon
American Society of Anesthesiologists score of ≥3
Inadequately corrected anticoagulation disorder or anticoagulation medication use
inability to provide informed consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michiel JH Maas, Msc
Phone
629647175
Ext
+31
Email
Michiel.maas@Radboudumc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter D Siersema, Prof
Organizational Affiliation
Radboud University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Radboud university medical center Nijmegen
City
Nijmegen
State/Province
Gelderland
ZIP/Postal Code
6500 HB
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michiel HJ Maas, MSc
Phone
629647175
Ext
+31
Email
Michiel.maas@Radboudumc.nl
First Name & Middle Initial & Last Name & Degree
Peter D. Siersema, prof.
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
The dataset used during this study is available from the corresponding author upon reasonable request.
Learn more about this trial
Synergistic Effect of G-Eye Balloon for Behind the Folds Visualization With CADe (Discovery System) on Adenoma Detection Rate.
We'll reach out to this number within 24 hrs